Organogenesis announces FDA acceptance of ReNu biologics license application
Organogenesis announced that the FDA has completed their filing determination and accepted for review the company's biologics license application, or BLA, for ReNu, a cryopreserved, amniotic suspension allograft developed for the treatment of pain in symptomatic knee osteoarthritis. The FDA has set a Prescription Drug